Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04074096 | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis(BEPCOME-MB) | active not recruiting | Phase 2 | 10 | UNICANCEROTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07628894 | Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy | not yet recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 |
| clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | available | — | — | xCuresINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | terminated | Phase 2 | 18 | Yale UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06319196 | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma(ClearMe) | recruiting | Phase 2 | 54 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07237594 | IL-17 Blockade to Decrease irAEs (REPLAY)(REPLAY) | recruiting | Phase 1 | 4 | Duke UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma(DUET-MEL) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT01009177 | Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC) | completed | Phase 2 | 80 | ActelionINDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03958383 | IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma | terminated | Phase 1 / Phase 2 | 8 | University of Wisconsin, MadisonOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06897735 | Exploratory Study of Inhaled Afatinib Dimaleate PK Profile(EDDIS-a1) | terminated | Phase 1 | 4 | Petrov, AndreyOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03771859 | A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed | completed | — | 152 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06400550 | Identification of Metabolic Phenotypes Associated With Melanoma Metastasis | recruiting | — | 400 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07619898 | PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure(PHOENIX-ECP) | not yet recruiting | Phase 2 | 112 | Therakos LLCINDUSTRY | 0 | Jun 2, 2026 | clinicaltrials |
| NCT03467516 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 34 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | terminated | Phase 1 / Phase 2 | 13 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05542342 | Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.(SITISVEAL) | completed | Phase 2 | 16 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05912244 | A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma | active not recruiting | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02073123 | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 131 | NewLink Genetics CorporationINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT02645149 | Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma(Match Mel) | completed | Phase 2 | 216 | Melanoma Institute AustraliaOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06608511 | Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | active not recruiting | — | 20 | University of Wisconsin, MadisonOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07615881 | Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma(IpiD) | not yet recruiting | Phase 1 / Phase 2 | 18 | Amsterdam UMC, location VUmcOTHER | 0 | May 29, 2026 | clinicaltrials |
| NCT04305054 | Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 335 | Merck Sharp & Dohme LLCINDUSTRY | 14 | May 28, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT00600496 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | completed | Phase 1 | 140 | AstraZenecaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT07422805 | Circulating Tumor DNA in Melanoma Patients(ctDNA) | active not recruiting | Phase 1 / Phase 2 | 176 | Institute of Oncology LjubljanaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03941756 | Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma | recruiting | N/A | 252 | M.D. Anderson Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06391099 | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer | suspended | N/A | 60 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03336606 | Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | completed | Phase 1 | 13 | Providence Health & ServicesOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03941379 | A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | active not recruiting | — | 63 | Aura BiosciencesINDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT04611568 | War on Melanoma™ Public Health & Education Campaign | active not recruiting | N/A | 75,000 | OHSU Knight Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05053555 | High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies | recruiting | N/A | 60 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | active not recruiting | Phase 2 | 237 | Cogent Biosciences, Inc.INDUSTRY | 15 | May 22, 2026 | clinicaltrials |
| NCT05225428 | Video Education With Result Dependent dIsclosure(VERDI) | recruiting | N/A | 1,020 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05498792 | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | recruiting | Early Phase 1 | 12 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02965716 | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | active not recruiting | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | May 20, 2026 | clinicaltrials |
| NCT04253080 | Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors(ENZYMELA) | completed | N/A | 127 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04751396 | Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors | recruiting | — | 125 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06712927 | Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | recruiting | Phase 2 | 60 | Stanford UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07099430 | A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma | recruiting | Phase 1 / Phase 2 | 200 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | terminated | Phase 2 | 225 | Iovance Biotherapeutics, Inc.INDUSTRY | 7 | May 15, 2026 | clinicaltrials |
| NCT06043947 | Survival Monitoring in Russian Cancer Registries(SURVIMON) | active not recruiting | — | 100,000 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval | available | — | — | Agenus Inc.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT06889766 | NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma(LauT1) | recruiting | Phase 1 | 9 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06594991 | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | recruiting | Phase 2 | 88 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07581509 | Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma | not yet recruiting | Phase 1 | 138 | Biocon Biologics UK PLCINDUSTRY | 0 | May 14, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 5, 2026source: clinicaltrials